CA2376192A1 - Fusions de genes exprimees par la streptavidine et methodes pour les utiliser - Google Patents

Fusions de genes exprimees par la streptavidine et methodes pour les utiliser Download PDF

Info

Publication number
CA2376192A1
CA2376192A1 CA002376192A CA2376192A CA2376192A1 CA 2376192 A1 CA2376192 A1 CA 2376192A1 CA 002376192 A CA002376192 A CA 002376192A CA 2376192 A CA2376192 A CA 2376192A CA 2376192 A1 CA2376192 A1 CA 2376192A1
Authority
CA
Canada
Prior art keywords
streptavidin
fusion protein
antibody
amino acids
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002376192A
Other languages
English (en)
Inventor
Stephen Charles Goshorn
Scott Stoll Graves
Joanne Elaine Schultz
Yukang Lin
James Allen Sanderson
John M. Reno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Poniard Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2376192A1 publication Critical patent/CA2376192A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/36—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Nanotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des vecteurs servant à exprimer des cassettes de fusion issues de la streptavidine génomique. Divers modes de réalisation de l'invention décrivent des protéines de fusion obtenues à partir de ces vecteurs. Des modes de réalisation particuliers décrivent des protéines de fusion comprenant un anticorps à chaîne unique et la streptavidine génomique, ainsi que des vecteurs codant lesdites protéines. L'invention concerne en outre des méthodes d'utilisation des protéines de fusion de l'invention et, notamment, l'utilisation de protéines de fusion scFvSA comme marqueurs de diagnostic ou comme agents de ciblage spécifiques à une cellule.
CA002376192A 1999-06-07 2000-06-05 Fusions de genes exprimees par la streptavidine et methodes pour les utiliser Abandoned CA2376192A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13790099P 1999-06-07 1999-06-07
US60/137,900 1999-06-07
US16897699P 1999-12-03 1999-12-03
US60/168,976 1999-12-03
PCT/US2000/015595 WO2000075333A1 (fr) 1999-06-07 2000-06-05 Fusions de genes exprimees par la streptavidine et methodes pour les utiliser

Publications (1)

Publication Number Publication Date
CA2376192A1 true CA2376192A1 (fr) 2000-12-14

Family

ID=26835691

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002376192A Abandoned CA2376192A1 (fr) 1999-06-07 2000-06-05 Fusions de genes exprimees par la streptavidine et methodes pour les utiliser

Country Status (5)

Country Link
EP (1) EP1190061A1 (fr)
JP (1) JP2003501096A (fr)
AU (1) AU5597500A (fr)
CA (1) CA2376192A1 (fr)
WO (1) WO2000075333A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022087154A1 (fr) * 2020-10-20 2022-04-28 Repertoire Immune Medicines, Inc. Multimères peptidiques de classe ii du cmh et leurs utilisations
EP4171751A4 (fr) * 2020-06-24 2024-07-24 Repertoire Immune Medicines Inc Constructions d'expression de multimères du cmh et leurs utilisations

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002365844A1 (en) * 2001-12-07 2003-06-17 Antoine Noujaim Compositions and methods for producing vascular occlusion
AU2003208415B2 (en) * 2002-02-14 2009-05-28 Immunomedics, Inc. Anti-CD20 antibodies and fusion proteins thereof and methods of use
WO2008001802A1 (fr) 2006-06-27 2008-01-03 Asahi Kasei Kabushiki Kaisha Substrat pour traitement de fluide biologique
CN101939336B (zh) * 2007-11-12 2014-05-14 U3制药有限公司 Axl抗体
NO2399993T3 (fr) * 2009-02-20 2018-02-17
US8841424B2 (en) 2009-05-11 2014-09-23 U3 Pharma Gmbh Humanized AXL antibodies
DE102009047243A1 (de) 2009-11-27 2011-06-01 Orgentec Diagnostika Gmbh Monospezifische Polypeptidreagenzien

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3583940D1 (de) * 1984-10-02 1991-10-02 Harry M Meade Herstellung von streptavidinaehnlichen polypeptiden.
US4839293A (en) * 1986-02-24 1989-06-13 The Trustees Of Columbia University In The City Of New York DNA encoding streptavidin, streptavidin produced therefrom, fused polypeptides which include amino acid sequences present in streptavidin and uses thereof
EP0644938A1 (fr) * 1992-05-29 1995-03-29 E.I. Du Pont De Nemours And Company PRODUCTION DE STREPTAVIDINE A PARTIR DU $i(BACILLUS SUBTILIS)
ATE210464T1 (de) * 1992-06-09 2001-12-15 Neorx Corp BIOTIN-DOTA KONJUGATE UND DEREN VERWENDUNG IN ßPRETARGETINGß VERFAHREN
WO1995015770A1 (fr) * 1993-12-09 1995-06-15 Neorx Corporation Procedes et composes de preciblage
AU7566396A (en) * 1995-11-16 1997-06-05 Boehringer Mannheim Gmbh Process for the preparation of peptides by way of streptavidin fusion proteins
US6497881B1 (en) * 1995-11-30 2002-12-24 New York University High efficiency tissue specific compound delivery system using streptavidin-protein a fusion protein
US6451995B1 (en) * 1996-03-20 2002-09-17 Sloan-Kettering Institute For Cancer Research Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4171751A4 (fr) * 2020-06-24 2024-07-24 Repertoire Immune Medicines Inc Constructions d'expression de multimères du cmh et leurs utilisations
WO2022087154A1 (fr) * 2020-10-20 2022-04-28 Repertoire Immune Medicines, Inc. Multimères peptidiques de classe ii du cmh et leurs utilisations

Also Published As

Publication number Publication date
EP1190061A1 (fr) 2002-03-27
JP2003501096A (ja) 2003-01-14
WO2000075333A9 (fr) 2002-06-20
WO2000075333A1 (fr) 2000-12-14
AU5597500A (en) 2000-12-28

Similar Documents

Publication Publication Date Title
US7144991B2 (en) Streptavidin expressed gene fusions and methods of use thereof
WO2003050260A2 (fr) Fusions de genes exprimees par la streptavidine et leurs procedes d'utilisation
Dübel et al. Bifunctional and multimeric complexes of streptavidin fused to single chain antibodies (scFv)
US5608039A (en) Single chain B3 antibody fusion proteins and their uses
US6083477A (en) Non-antigenic toxin-conjugate and fusion protein of internalizing receptor system
EP3231812B1 (fr) Exotoxine de pseudomonas ayant moins d'épitopes immunogènes de lymphocytes t et/ou de lymphocytes b
AU2006275865B2 (en) Mutated Pseudomonas exotoxins with reduced antigenicity
KR102342935B1 (ko) 항체-약물 접합체 및 면역독소
US5889157A (en) Humanized B3 antibody fragments, fusion proteins, and uses thereof
EP2755993B1 (fr) Exotoxine a de pseudomonas des épitopes de cellules b moins immunogènes
JP2021508458A (ja) Ｒｏｒ１特異性抗原結合分子
US5792456A (en) Mutant BR96 antibodies reactive with human carcinomas
JP2016190839A (ja) 細胞表面の前立腺特異的膜抗原に対するモノクローナル抗体および単鎖抗体フラグメント
CN106432502B (zh) 用于治疗cea阳性表达肿瘤的双特异纳米抗体
WO1999051643A1 (fr) Molecules chimeres mutagenisees a base d'il-13
JP2003524587A (ja) 多発性骨髄腫を処置するための、ｃｄ３８に対する、遺伝子操作した抗体の使用
Albrecht et al. Monospecific bivalent scFv-SH: effects of linker length and location of an engineered cysteine on production, antigen binding activity and free SH accessibility
AU2005216126A1 (en) Binding peptidomimetics and uses of the same
Brinkmann et al. Recombinant immunotoxins containing the VH or VL domain of monoclonal antibody B3 fused to Pseudomonas exotoxin.
CA2376192A1 (fr) Fusions de genes exprimees par la streptavidine et methodes pour les utiliser
Barth et al. Construction and in vitro evaluation of RFT5 (scFv)-ETA', a new recombinant single-chain immunotoxin with specific cytotoxicity toward CD25+ Hodgkin-derived cell lines.
Goshorn et al. Preclinical evaluation of a humanized NR-LU-10 antibody-streptavidin fusion protein for pretargeted cancer therapy
KR102353086B1 (ko) 신규 면역독소 제조방법
US5728821A (en) Mutant BR96 antibodies reactive with human carcinomas
JP2024532602A (ja) 天然分子に近いポリペプチド融合分子

Legal Events

Date Code Title Description
FZDE Discontinued